• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HIN
Click for more information
0.00% $2.37

HEARTWARE INTERNATIONAL, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
HINSuspension from Official Quotation - Close of trading 10/09PRICE SENSITIVE10/09/13
HINUS FDA Grants HeartWare Full Approval for Protocol to SupplePRICE SENSITIVE28/08/13
HINAppendix 4D and Half Year Financial StatementPRICE SENSITIVE12/08/13
HINReports 2013 Q2 Rev of US$50.8M vs US$29.1M in Q2 2012PRICE SENSITIVE09/08/13
HINUS FDA Grants Conditional Approval to Enroll Supplemental CoPRICE SENSITIVE18/06/13
HINHeartWare to Delist from Australian Securities ExchangePRICE SENSITIVE13/06/13
HINReports 2013 Q1 Rev of US$49.2M vs US$26.4M in Q1 2012PRICE SENSITIVE30/04/13
HINProspectus for Public Offering of HeartWare Common StockPRICE SENSITIVE14/03/13
HINPricing of Public Offering of Common StockPRICE SENSITIVE13/03/13
HINHeartWare Announces Public Offering of Common StockPRICE SENSITIVE12/03/13
HINAnnual Report for 2012 and ASX Appendix 4EPRICE SENSITIVE28/02/13
HINReports 2012 Revenue of US$110.9M vs US$82.8M in 2011PRICE SENSITIVE28/02/13
HINHeartWare Announces Preliminary Q4 2012 Revenues of US$32MilPRICE SENSITIVE08/01/13
HINHeartWare Receives U.S. FDA Approval For HVAD PumpPRICE SENSITIVE21/11/12
HINReports 2012 Q3 Rev of US$ 22.9 M vs. US$ 21.3 M in 2011 Q3PRICE SENSITIVE12/11/12
HINHeartWare to Withdraw Participation in Pilot Study Revive-ItPRICE SENSITIVE16/10/12
HINAppendix 4D and Half Year Financial StatementPRICE SENSITIVE09/08/12
HINReports 2012 Q2 Rev of US$29.1 M vs US$20.4 M in 2011 Q2PRICE SENSITIVE08/08/12
HINHeartWare Completes Acquisition of World Heart CorpPRICE SENSITIVE03/08/12
HINHeartWare Announces Publication of Data from U.S. Bridge toPRICE SENSITIVE24/05/12
HINHeartWare Receives CE Mark Addendum For Label ExpansionPRICE SENSITIVE24/05/12
HINReports 2012 Q1 Rev of US$26.3 M vs US$18.0M in Q1 of 2011PRICE SENSITIVE11/05/12
HINHeartWare Completes Enrollment in Destination Therapy StudyPRICE SENSITIVE09/05/12
HINHeartWare Receives Favorable US FDA Panel VotePRICE SENSITIVE26/04/12
HINHeartWare Enters Agreement to Acquire WorldHeart for US$8MPRICE SENSITIVE30/03/12
HINHeartWare Receives New CAP Allotment from FDA for Bridge toPRICE SENSITIVE19/03/12
HINAnnual Report for 2011 and ASX Appendix 4EPRICE SENSITIVE28/02/12
HINReports Q4 Rev of US$23.1M and Annual 2011 Rev of US$82.8MPRICE SENSITIVE17/02/12
HINHeartWare Announces Date for FDA Advisory Committee PanelPRICE SENSITIVE15/02/12
HINQ4 2011 Preliminary Revenue and JPM ConferencePRICE SENSITIVE10/01/12
HINHeartWare and Dualis Announce Development AgreementPRICE SENSITIVE10/01/12
HINThird Quarter 2011 Financial ResultsPRICE SENSITIVE04/11/11
HINHeartWare Announces Third Quarter Revenues of US$21.3 MPRICE SENSITIVE28/10/11
HINHeartWare Announces Planned Departure of CFOPRICE SENSITIVE28/10/11
HINHeartWare Announces Updated Clinical Data Presented at EACTSPRICE SENSITIVE03/10/11
HINPreclinical Data for Next Generation MVAD Pump PresentedPRICE SENSITIVE12/09/11
HINAppendix 4D and Half Year Financial StatementPRICE SENSITIVE08/08/11
HINReports Second Quarter 2011 Revenues of US$20.4 MillionPRICE SENSITIVE05/08/11
HINReimbursement Approval in FrancePRICE SENSITIVE28/06/11
HINWebcast slides (with clinical update) from Wells Fargo 2011PRICE SENSITIVE23/06/11
HINReports First Quarter 2011 Revenues of US$18 MillionPRICE SENSITIVE06/05/11
HINHeartWare Supplemental Addendum to CE Mark Accepted by BSIPRICE SENSITIVE27/04/11
HINHeartWare BTT and CAP data presented at ISHLT 2011PRICE SENSITIVE18/04/11
HINHeartWare receives approval from TGA in AustraliaPRICE SENSITIVE25/03/11
HINU.S. FDA accepts HeartWare PMA filing for reviewPRICE SENSITIVE18/03/11
HINAnnual Report for 2010 and ASX Appendix 4EPRICE SENSITIVE28/02/11
HINReports Q4 rev. of US$20.9M and annual rev. of US$55MPRICE SENSITIVE25/02/11
HINFDA Grants HeartWare 94-Patient Allotment for BTT CAPPRICE SENSITIVE25/01/11
HINQ4 2010 Preliminary Revenue and JPM ConferencePRICE SENSITIVE11/01/11
HINHeartWare Submits PMA to FDA for Bridge-to-TransplantPRICE SENSITIVE29/12/10
HINCompletion of Concurrent Public OfferingsPRICE SENSITIVE16/12/10
HINHeartWare Announces Pricing of Concurrent Public OfferingsPRICE SENSITIVE14/12/10
HINHeartWare Announces Concurrent Public OfferingsPRICE SENSITIVE10/12/10
HINHeartWare Bridge-to-Transplant Data AnnouncementPRICE SENSITIVE15/11/10
HINThird Quarter ResultsPRICE SENSITIVE04/11/10
HINFDA Grants HeartWare Second Patient Allotment Under CAPPRICE SENSITIVE06/09/10
HINAppendix 4D and Half Year Financial Statements (US GAAP)PRICE SENSITIVE09/08/10
HINHeartWare Announces Second Quarter ResultsPRICE SENSITIVE06/08/10
HINHeartWare To Commence Destination Therapy TrialPRICE SENSITIVE15/06/10
HINFirst Quarter 2010 Financial StatementsPRICE SENSITIVE05/05/10
HINFirst Quarter ResultsPRICE SENSITIVE04/05/10
HINInitiates voluntary repairs and recalls certain controllersPRICE SENSITIVE27/04/10
HINFirst 100 Patient Commercial and Clinical DataPRICE SENSITIVE27/04/10
HINFDA Approves Continued Access Protocol for BTTPRICE SENSITIVE08/04/10
HINAnnual Report for 2009 and ASX Appendix 4EPRICE SENSITIVE24/02/10
HINReports Q4 Rev. of US$12.2M and Annual Rev. of US$24.2MPRICE SENSITIVE23/02/10
HINPricing of Public Offering of Common StockPRICE SENSITIVE28/01/10
HINProspectus for Public Offering of HeartWare Common StockPRICE SENSITIVE27/01/10
HINPublic Offering of HeartWare Common StockPRICE SENSITIVE27/01/10
HINHeartWare files IDE for Destination TherapyPRICE SENSITIVE24/11/09
HINRevenues of US$7.5M for Quarter Ended 30 September 2009PRICE SENSITIVE05/11/09
HINFDA Approves Expansion to 40 Sites for US BTT TrialPRICE SENSITIVE06/10/09
HINReinstatement to Official QuotationPRICE SENSITIVE02/09/09
HINHeartWare Surpasses 50 US ImplantsPRICE SENSITIVE21/08/09
HINASX Append. 4D And Half Year Financial Statements (US GAAP)PRICE SENSITIVE17/08/09
HINUS$55 Million Capital RaisingPRICE SENSITIVE11/08/09
HINJoint Termination of MergerPRICE SENSITIVE03/08/09
HINQuarterly Update And ASX Appendix 4CPRICE SENSITIVE31/07/09
HINUS FTC to Challenge Thoratec Acquisition of HeartWarePRICE SENSITIVE30/07/09
HINTrading HaltPRICE SENSITIVE30/07/09
HINQuarterly Update April 2009 and ASX Appendix 4CPRICE SENSITIVE30/04/09
HINEuropean Clinical Data UpdatePRICE SENSITIVE27/04/09
HINFirst International Sales and US Clinical Trial UpdatePRICE SENSITIVE31/03/09
HIN2008 Preliminary Final ReportPRICE SENSITIVE27/02/09
HINHeartWare to be Acquired By Thoratec Corporation for US$282PRICE SENSITIVE16/02/09
HINTrading HaltPRICE SENSITIVE13/02/09
HINQuarterly CEO UpdatePRICE SENSITIVE30/01/09
HINCE Mark Approval ReceivedPRICE SENSITIVE30/01/09
HINSuspension from Official Quotation - Close of trading 10/09
10/09/13PRICE SENSITIVE
HINUS FDA Grants HeartWare Full Approval for Protocol to Supple
28/08/13PRICE SENSITIVE
HINAppendix 4D and Half Year Financial Statement
12/08/13PRICE SENSITIVE
HINReports 2013 Q2 Rev of US$50.8M vs US$29.1M in Q2 2012
09/08/13PRICE SENSITIVE
HINUS FDA Grants Conditional Approval to Enroll Supplemental Co
18/06/13PRICE SENSITIVE
HINHeartWare to Delist from Australian Securities Exchange
13/06/13PRICE SENSITIVE
HINReports 2013 Q1 Rev of US$49.2M vs US$26.4M in Q1 2012
30/04/13PRICE SENSITIVE
HINProspectus for Public Offering of HeartWare Common Stock
14/03/13PRICE SENSITIVE
HINPricing of Public Offering of Common Stock
13/03/13PRICE SENSITIVE
HINHeartWare Announces Public Offering of Common Stock
12/03/13PRICE SENSITIVE
HINAnnual Report for 2012 and ASX Appendix 4E
28/02/13PRICE SENSITIVE
HINReports 2012 Revenue of US$110.9M vs US$82.8M in 2011
28/02/13PRICE SENSITIVE
HINHeartWare Announces Preliminary Q4 2012 Revenues of US$32Mil
08/01/13PRICE SENSITIVE
HINHeartWare Receives U.S. FDA Approval For HVAD Pump
21/11/12PRICE SENSITIVE
HINReports 2012 Q3 Rev of US$ 22.9 M vs. US$ 21.3 M in 2011 Q3
12/11/12PRICE SENSITIVE
HINHeartWare to Withdraw Participation in Pilot Study Revive-It
16/10/12PRICE SENSITIVE
HINAppendix 4D and Half Year Financial Statement
09/08/12PRICE SENSITIVE
HINReports 2012 Q2 Rev of US$29.1 M vs US$20.4 M in 2011 Q2
08/08/12PRICE SENSITIVE
HINHeartWare Completes Acquisition of World Heart Corp
03/08/12PRICE SENSITIVE
HINHeartWare Announces Publication of Data from U.S. Bridge to
24/05/12PRICE SENSITIVE
HINHeartWare Receives CE Mark Addendum For Label Expansion
24/05/12PRICE SENSITIVE
HINReports 2012 Q1 Rev of US$26.3 M vs US$18.0M in Q1 of 2011
11/05/12PRICE SENSITIVE
HINHeartWare Completes Enrollment in Destination Therapy Study
09/05/12PRICE SENSITIVE
HINHeartWare Receives Favorable US FDA Panel Vote
26/04/12PRICE SENSITIVE
HINHeartWare Enters Agreement to Acquire WorldHeart for US$8M
30/03/12PRICE SENSITIVE
HINHeartWare Receives New CAP Allotment from FDA for Bridge to
19/03/12PRICE SENSITIVE
HINAnnual Report for 2011 and ASX Appendix 4E
28/02/12PRICE SENSITIVE
HINReports Q4 Rev of US$23.1M and Annual 2011 Rev of US$82.8M
17/02/12PRICE SENSITIVE
HINHeartWare Announces Date for FDA Advisory Committee Panel
15/02/12PRICE SENSITIVE
HINQ4 2011 Preliminary Revenue and JPM Conference
10/01/12PRICE SENSITIVE
HINHeartWare and Dualis Announce Development Agreement
10/01/12PRICE SENSITIVE
HINThird Quarter 2011 Financial Results
04/11/11PRICE SENSITIVE
HINHeartWare Announces Third Quarter Revenues of US$21.3 M
28/10/11PRICE SENSITIVE
HINHeartWare Announces Planned Departure of CFO
28/10/11PRICE SENSITIVE
HINHeartWare Announces Updated Clinical Data Presented at EACTS
03/10/11PRICE SENSITIVE
HINPreclinical Data for Next Generation MVAD Pump Presented
12/09/11PRICE SENSITIVE
HINAppendix 4D and Half Year Financial Statement
08/08/11PRICE SENSITIVE
HINReports Second Quarter 2011 Revenues of US$20.4 Million
05/08/11PRICE SENSITIVE
HINReimbursement Approval in France
28/06/11PRICE SENSITIVE
HINWebcast slides (with clinical update) from Wells Fargo 2011
23/06/11PRICE SENSITIVE
HINReports First Quarter 2011 Revenues of US$18 Million
06/05/11PRICE SENSITIVE
HINHeartWare Supplemental Addendum to CE Mark Accepted by BSI
27/04/11PRICE SENSITIVE
HINHeartWare BTT and CAP data presented at ISHLT 2011
18/04/11PRICE SENSITIVE
HINHeartWare receives approval from TGA in Australia
25/03/11PRICE SENSITIVE
HINU.S. FDA accepts HeartWare PMA filing for review
18/03/11PRICE SENSITIVE
HINAnnual Report for 2010 and ASX Appendix 4E
28/02/11PRICE SENSITIVE
HINReports Q4 rev. of US$20.9M and annual rev. of US$55M
25/02/11PRICE SENSITIVE
HINFDA Grants HeartWare 94-Patient Allotment for BTT CAP
25/01/11PRICE SENSITIVE
HINQ4 2010 Preliminary Revenue and JPM Conference
11/01/11PRICE SENSITIVE
HINHeartWare Submits PMA to FDA for Bridge-to-Transplant
29/12/10PRICE SENSITIVE
HINCompletion of Concurrent Public Offerings
16/12/10PRICE SENSITIVE
HINHeartWare Announces Pricing of Concurrent Public Offerings
14/12/10PRICE SENSITIVE
HINHeartWare Announces Concurrent Public Offerings
10/12/10PRICE SENSITIVE
HINHeartWare Bridge-to-Transplant Data Announcement
15/11/10PRICE SENSITIVE
HINThird Quarter Results
04/11/10PRICE SENSITIVE
HINFDA Grants HeartWare Second Patient Allotment Under CAP
06/09/10PRICE SENSITIVE
HINAppendix 4D and Half Year Financial Statements (US GAAP)
09/08/10PRICE SENSITIVE
HINHeartWare Announces Second Quarter Results
06/08/10PRICE SENSITIVE
HINHeartWare To Commence Destination Therapy Trial
15/06/10PRICE SENSITIVE
HINFirst Quarter 2010 Financial Statements
05/05/10PRICE SENSITIVE
HINFirst Quarter Results
04/05/10PRICE SENSITIVE
HINInitiates voluntary repairs and recalls certain controllers
27/04/10PRICE SENSITIVE
HINFirst 100 Patient Commercial and Clinical Data
27/04/10PRICE SENSITIVE
HINFDA Approves Continued Access Protocol for BTT
08/04/10PRICE SENSITIVE
HINAnnual Report for 2009 and ASX Appendix 4E
24/02/10PRICE SENSITIVE
HINReports Q4 Rev. of US$12.2M and Annual Rev. of US$24.2M
23/02/10PRICE SENSITIVE
HINPricing of Public Offering of Common Stock
28/01/10PRICE SENSITIVE
HINProspectus for Public Offering of HeartWare Common Stock
27/01/10PRICE SENSITIVE
HINPublic Offering of HeartWare Common Stock
27/01/10PRICE SENSITIVE
HINHeartWare files IDE for Destination Therapy
24/11/09PRICE SENSITIVE
HINRevenues of US$7.5M for Quarter Ended 30 September 2009
05/11/09PRICE SENSITIVE
HINFDA Approves Expansion to 40 Sites for US BTT Trial
06/10/09PRICE SENSITIVE
HINReinstatement to Official Quotation
02/09/09PRICE SENSITIVE
HINHeartWare Surpasses 50 US Implants
21/08/09PRICE SENSITIVE
HINASX Append. 4D And Half Year Financial Statements (US GAAP)
17/08/09PRICE SENSITIVE
HINUS$55 Million Capital Raising
11/08/09PRICE SENSITIVE
HINJoint Termination of Merger
03/08/09PRICE SENSITIVE
HINQuarterly Update And ASX Appendix 4C
31/07/09PRICE SENSITIVE
HINUS FTC to Challenge Thoratec Acquisition of HeartWare
30/07/09PRICE SENSITIVE
HINTrading Halt
30/07/09PRICE SENSITIVE
HINQuarterly Update April 2009 and ASX Appendix 4C
30/04/09PRICE SENSITIVE
HINEuropean Clinical Data Update
27/04/09PRICE SENSITIVE
HINFirst International Sales and US Clinical Trial Update
31/03/09PRICE SENSITIVE
HIN2008 Preliminary Final Report
27/02/09PRICE SENSITIVE
HINHeartWare to be Acquired By Thoratec Corporation for US$282
16/02/09PRICE SENSITIVE
HINTrading Halt
13/02/09PRICE SENSITIVE
HINQuarterly CEO Update
30/01/09PRICE SENSITIVE
HINCE Mark Approval Received
30/01/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.